EUVIMEDEUVIMED entdecken
Open Access

The Interplay of Heart Failure and Lung Disease: Clinical Correlations, Mechanisms, and Therapeutic Implications

Salma Ahmad, Ayman Isbatan, Sunny Chen, Steven M Dudek, Richard D Minshall, Jiwang Chen

Journal of Respiratory Biology and Translational Medicine · 2024

DOI: 10.70322/jrbtm.2024.10020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Respiratory Biology and Translational Medicine, 2024. Verfasst von Salma Ahmad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, University of Illinois at Chicago, Chicago, IL 60612, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a common clinical syndrome marked by reduced cardiac output, elevated intracardiac pressures, and heart dysfunction. Chronic HF (CHF) is a syndrome characterized by a lack of blood flow and impaired pumping ability to the heart over time, while acute HF (AHF) arises suddenly due to incidents like myocardial infarction or cardiac arrest. HF has a significant impact on pulmonary health and function, leading to conditions such as pulmonary edema and restrictive lung patterns. Clinical evidence highlights the bidirectional relationship between HF and lung dysfunction. Declining lung function serves as a predictor for HF progression and severity, while HF contributes to worsening lung health. Animal models that induce HF through surgical methods further demonstrate the connection between heart and lung pathology. The main mechanisms linking HF and lung dysfunction are pressure overload and chronic systemic inflammation, with changes in the extracellular matrix (ECM) also playing a role. Additionally, environmental factors like air pollution exacerbate lung inflammation, increasing the risk of both HF and chronic obstructive pulmonary disease (COPD) incidence. Combined treatment approaches involving pharmaceutical drugs such as statins, Angiotensin-converting enzyme (ACE) inhibitors, and Angiotensin receptor blockers (ARBs) may benefit by reducing inflammation. This review will explore the complex interplay between HF and lung function, emphasizing their interconnected pathophysiology and potential integrated treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

Acute heart failure (AHF)Chronic heart failure (CHF)Chronic systemic inflammationLung dysfunctionPressure overload

Autor:innen und Institutionen

  • Cardiovascular Research Center, University of Illinois at Chicago, Chicago, IL 60612, USA.
  • Division of Pulmonary, Critical Care Medicine, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
  • Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60612, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ahmad, S., Isbatan, A., Chen, S., Dudek, S. M., Minshall, R. D., & Chen, J. (2024). The Interplay of Heart Failure and Lung Disease: Clinical Correlations, Mechanisms, and Therapeutic Implications. Journal of Respiratory Biology and Translational Medicine. https://doi.org/10.70322/jrbtm.2024.10020

Vancouver

Ahmad S, Isbatan A, Chen S, Dudek SM, Minshall RD, Chen J. The Interplay of Heart Failure and Lung Disease: Clinical Correlations, Mechanisms, and Therapeutic Implications. Journal of Respiratory Biology and Translational Medicine. 2024. doi:10.70322/jrbtm.2024.10020

BibTeX
@article{Ahmad2024,
  author = {Ahmad, Salma and Isbatan, Ayman and Chen, Sunny and Dudek, Steven M and Minshall, Richard D and Chen, Jiwang},
  title = {The Interplay of Heart Failure and Lung Disease: Clinical Correlations, Mechanisms, and Therapeutic Implications},
  journal = {Journal of Respiratory Biology and Translational Medicine},
  year = {2024},
  doi = {10.70322/jrbtm.2024.10020}
}
Kostenlos starten →